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Abstract
Oral drugs are becoming increasingly common in oncology care. In contrast
to intravenous chemotherapy, which is administered in the clinic and carefully
tracked via structured electronic health records (EHRs), oral drug treatment is
self-administered and therefore not tracked as well. Often, the details of oral cancer
treatment occur only in unstructured clinic notes. Extracting this information is
critical to understanding a patient’s treatment history. Yet, this is a challenging
task because treatment intervals must be inferred longitudinally from both explicit
mentions in the text as well as from document timestamps. In this work, we
present TIFTI (Temporally Integrated Framework for Treatment Intervals), a robust
framework for extracting oral drug treatment intervals from a patient’s unstructured
notes. TIFTI leverages distinct sources of temporal information by breaking the
problem down into two separate subtasks: document-level sequence labeling and
date extraction. On a labeled dataset of metastatic renal-cell carcinoma (RCC)
patients, it exactly matched the labeled start date in 46% of the examples (86% of
the examples within 30 days), and it exactly matched the labeled end date in 52%
of the examples (78% of the examples within 30 days). Without retraining, the
model achieved a similar level of performance on a labeled dataset of advanced
non-small-cell lung cancer (NSCLC) patients.
1 Introduction
The widespread adoption of electronic health records (EHRs) has raised hopes that data from routine
clinical practice can be used to better understand the effectiveness of drugs in real-world settings. This
is particularly important in cancer care, where treatment landscapes for many diseases have evolved
rapidly [6]. In renal cell carcinoma (RCC), for example, ten new targeted drugs have been approved
since 2006, leaving clinicians in need of answers for how best to use these different treatments to
care for their patients [1]. Many of the new treatments for RCC and for other cancer types are oral
therapies, which patients take at home. Unfortunately, exposure to oral therapies is generally not well
captured in EHR structured data, but rather the information is buried in free text such as clinic visit
notes [10, 12]. Manual abstraction of oral therapy exposure data by a human expert is possible but
inefficient, so there is a need for automated approaches for extracting drug treatment information [7].
Most existing work on extracting drugs from EHRs has focused on discharge summaries, which
represent a single point in a patient’s clinical course [8, 9, 11, 12]. In contrast, understanding the
chronology of a disease such as cancer requires treatment information that is scattered longitudinally
across clinic notes. The modeling task we address is: given the name of a drug and a sequence of
time-stamped clinic visit notes, predict whether the patient took the drug and if so, generate the time
interval over which the patient took it. Our contribution is a framework called TIFTI (Temporally
Machine Learning for Health (ML4H) Workshop at NeurIPS 2018.
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Figure 1: Toy example of processed document timeline. The start date should be 12/08/18 because
the patient has been on the drug “for a week” as of the 12/15/18 note. The end date should be 1/28/19.
Integrated Framework for Treatment Intervals), which approaches this problem by combining the
output from two sub-tasks: a document-level sequence labeling task and a date extraction task.
2 Dataset
We conducted our study on the clinic visit notes of a set of 4,216 patients with metastatic RCC,
pulled from the Flatiron Health database, a longitudinal, demographically, and geographically diverse
database derived from EHR data. Institutional Review Board approval was obtained prior to study
conduct and informed patient consent was waived. Oral drug regimens, along with their start and end
dates, were abstracted by experts via chart review [2].1 For the purpose of developing and validating
an ML model, we used these labels as ground truth. The units of observation for our task were
patient-drug pairs. Only pairs in which the clinic notes contained at least one mention of the drug
(either by the generic or brand name) were considered. There were 8,259 such patient-drug examples
from 172 different practices. Of these, the drug was actually taken in 4,410 (53%) examples; in the
rest, the drug was mentioned in the notes but not taken.
3 Description of TIFTI
Start and stop dates for oral drug regimens can be inferred from clinic notes in two ways. The
first is via an explicit mention of an absolute or relative date, such as “Patient started DRUG on
12/8/18” or “Patient discontinued DRUG two weeks ago.” The second is via an implicit mention
of whether the drug is currently being taken, such as “Patient tolerating DRUG well” or “Patient
no longer on DRUG.” Both types of mentions are prevalent. In our data, we found that only about
half of the start and stop dates could be found via explicit mentions, meaning that the rest must
be inferred by anchoring implicit mentions to document timestamps. On the other hand, only 55%
of the start dates and 77% of the end dates corresponded to a document timestamp, meaning that
implicit mentions alone are also insufficient. Our analysis further found that different practices have
significantly different ways of recording oral drug regimens. This motivates the design of the TIFTI
framework, which combines document-level sequence labeling (for implicit mentions) with free text
date extraction and labeling (for explicit mentions).
Data Preprocessing TIFTI starts with a series of preprocessing steps for each patient-drug example.
First, it tokenizes the documents into sentences [3] and removes all documents and sentences without
a mention of the drug. Next, to remove the redundancy caused by “copy-forwarding” [4], it removes
any sentence that occurred previously. Finally, to reduce feature sparsity and ensure that model
features generalize across drugs, it replaces each mention of the drug (by any of its generic or brand
name synonyms) with the placeholder DRUG and each mention of other commonly taken drugs with
the placeholder OTHER-DRUG. We refer to the list of condensed documents that are output by this
preprocessing as the document timeline. A toy example is provided in Figure 1.
Document Timeline Sequence Labeling The first task modeled by TIFTI is a sequence labeling
task on the document timeline. Each document is labeled with one of three labels, depending on how
the document timestamp relates to the ground truth interval: PRE if it is before the start date, MID if it
falls within the interval, or POST if it is at or after the end date. A classification algorithm on this
task will output for each document a probability distribution across these labels. To translate these
probabilities to an interval prediction, the following algorithm can be used. First, the most probable
sequence of labels is found such that no MID precedes a PRE and no POST precedes a MID. Then, if
1See Appendix for which drugs were included.
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Figure 2: Time expression extraction, mapping, and labeling on the example from Figure 1.
Figure 3: Toy example of simulated version of the document timeline from Figure 1. Two pseudo-
documents, indicated in red, were added for sentences that corresponded to time expressions.
there are no MID or POST documents, the algorithm outputs that the drug was not taken. Otherwise,
the start date is set to the timestamp of the first document with a label of MID and the end date to the
timestamp of the first document with a label of POST (assuming one exists). If we use the document
timeline in Figure 1 to generate the labeled data for our training step, the first two documents would be
labeled as PRE, the next two as MID, and the final document as POST. Assuming the correct document
label sequence was predicted, the predicted start date would be 12/15/18 (timestamp of the first MID
document) and the predicted end date would be 1/28/19 (timestamp of the first POST document).
Time Expression Classification The second task modeled by TIFTI is a joint date extraction and
labeling task. The first step of this process is conducted using a regular expression-based temporal
tagger that categorizes possible time expression types into one of a few buckets, such as explicit
dates (e.g. “November 27”) and relative dates (e.g. “last Tuesday”) and then calculates the date the
expression is referring to, which we refer to as the mapped date. The left side of Figure 2 shows this
step on our toy example. The second step of the process is a three-class classification problem on the
sentence containing the time expression to determine whether the mapped time refers to the beginning
of a drug regimen, the end of a drug regimen, or neither. In each sentence, the time expression is
replaced with TIME BUCKET-NAME. We refer to this new sentence as a revised sentence. The
right side of Figure 2 shows this step on our toy example. Since there are no explicit ground truth
labels for whether the content of a revised sentence actually refers to the beginning or end of the
regimen, labels for training are generated using a noisy proxy: whether the mapped date is within
a small number of days (chosen as a hyperparameter and optimized on the development set) of the
labeled start or end date. At evaluation time, for each time expression, the time expression classifier
provides a probability estimate that the expression refers to a start date, end date, or neither.
Integrated Prediction Task TIFTI combines the output of the two sub-tasks. First, the time
expression classification algorithm is run. If the maximum probability of an expression being either a
start or an end date is above a threshold (chosen as a hyperparameter), TIFTI uses that start or end
date for its predicted interval. Otherwise, it creates a new simulated document timeline, where pseudo-
documents are added to the original document timeline. The contents of these pseudo-documents are
the revised sentences from the time expression classification approach, and their timestamps are the
mapped dates. A simulated document timeline for our toy example is shown in Figure 3. TIFTI then
runs an algorithm for the sequence labeling task on this simulated document timeline.
4 Experimental Setup
We used 80% of our RCC examples for development and reserved 20% for testing. The dataset was
split such that there was no patient-level overlap between development and test sets.
We measured the performance of the binary task of predicting whether the patient took the drug
using the F1 score. For true positive examples (those for which the model correctly predicted that the
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Table 1: Ablation study of TIFTI framework, applied to test set of 1,615 examples.
Method F1 Score Start(0) Stop(0) Start(30) Stop(30)
Timeline Labeling 0.943 23.8% 51.4% 82.5% 77.8%
Simulated Timeline Labeling 0.943 41.0% 52.2% 85.7% 77.2%
Expression Classification +
Timeline Labeling 0.946 44.7% 52.4% 83.6% 77.7%
Expression Classification +
Simulated Timeline Labeling (TIFTI) 0.944 45.8% 52.4% 85.9% 77.6%
patient took the drug), we measured the agreement of start and stop dates as follows. Let Starti(t)
and Stopi(t) be an indicator variable denoting whether for the i
th example, the predicted start or
stop date matches the ground truth date within a window of t days. For example, Stopi(7) = 1 iff
either the patient is still taking the drug and the model correctly identifies this, or the last-taken date
identified by the model is within a week of the ground truth. To measure overall date agreement,
we used Start(t) and Stop(t), defined to be the mean over the true positives of the Starti(t) and
Stopi(t) values.
To remain flexible and sensitive to dataset size, the TIFTI framework does not specify the classification
algorithm for either sub-task. We tried multiple algorithms for each. On the document timeline
sequence labeling task, we saw the best performance with a bidirectional LSTM [5] over documents
featurized by ngrams. On the time expression classification task, we saw the best performance with a
simple `2-regularized logistic regression, also featurized by ngrams. These optimizations, along with
other hyperparameter tuning, were performed using 5-fold cross validation over the development set,
optimizing on a combination of the F1 score, Start(0), and Stop(0).
To perform well for rare drugs and generalize across diseases, TIFTI abstracts away the drug name
during feature generation and models each drug independently. To test whether this design had
the intended effect, we created a dataset of 8,388 advanced non-small cell lung cancer (NSCLC)
examples (6,810 in the development set and 1,578 in the test set), using the same data preprocessing
and feature generation process as for RCC. We then measured the performance on the NSCLC test
set of the final TIFTI model trained on RCC and of a TIFTI model trained on NSCLC examples.
5 Results
On the RCC test set, the full TIFTI model achieved an F1 score of 0.944, a Start(0) score of
45.8%, a Stop(0) score of 52.4%, a Start(30) score of 85.9%, and a Stop(30) score of 77.6%. We
performed an ablation study (Table 1) on our framework to demonstrate the value added by: (i) the
simulated timelines and (ii) the explicitly cascaded expression classification. The explicitly cascaded
models performed best, and the models with the simulated document timelines outperformed their
counterparts with the original document timeline, both at 0 and 30 days, confirming that pseudo-
documents add useful context. This effect is only visible for the start date statistics, which is consistent
with the fact that start dates were more likely than stop dates to be explicitly mentioned in text.
On the NSCLC test set, the model trained on the RCC data achieved an F1 score of 0.936, a Start(0)
score of 49.1%, and a Stop(0) score of 57.1%. This performance is comparable to the performance
on the RCC test set and almost as high as the model trained on the NSCLC examples (F1: 0.947,
Start(0): 50.3%, Stop(0): 57.8%), indicating that the framework generalized as intended.
6 Conclusion
We introduced TIFTI, a framework for extracting the spans of drug regimens from longitudinal
clinic visit notes. TIFTI predicts the treatment interval over a simulated patient timeline formed
by combining the temporal information from both free text and document timestamps. In our
experiments, it predicted approximately 80% of dates within 30 days and generalized to a new type
of cancer. This work is significant in that this framework could be applied to build EHR datasets that
capture exposure to anti-cancer therapies. Such datasets can then be de-identified and analyzed to
understand the real-world patient experience and develop insights that can impact cancer care.
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7 Appendix: Included Oral Drugs
For RCC, the oral drugs included were axitinib, cabozantinib, erlotinib, everolimus, lenvatinib,
pazopanib, sorafenib, and sunitinib. For NSCLC, the oral drugs included were afatinib, alectinib,
brigatinib, ceritinib, crizotinib, erlotinib, gefitinib, osimeritinib, cabozantinib, dabrafenib, trametinib,
vandetanib, and vemurafenib.
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